Frequency of Symptoms of Ovarian Cancer in Women Presenting to Primary Care Clinics
7
EPITHELIAL OVARIAN CANCER SIGNS
8
OVARIAN CANCER CLASSIFICATION
9
Epithelial Ovarian Cancer Cont... Five main histologic subtypes
10
Regulatory Pathways
11
Mucinous Carcinoma
12
Standard of Care
13
Chemotherapy Recurrent Disease Platinum Sensitive
14
Conventional Chemotherapy Side Effects
15
Cost Comparison Among Ovarian Cancer Treatments
16
Hereditary Susceptibility to
17
Clinical manifestation of hereditary ovarian cancer
18
LIFETIME RISK ESTIMATED IN BRCA1 & BRCA2 CARRIERS
19
BRCA1-RELATED OVARIAN CANCER
20
Hereditary breast and ovarian cancer syndrome (HBOC)
21
Targeted Therapies
22
Poly(ADP-Ribose) Polymerase (PARP) inhibition in ovarian cancer
23
PARP Inhibitors: Mechanism of Action
24
PARP Family
25
PARP Inhibitors Background
26
High Grade Serous Cancers (HGSC) & BRCA mutations
27
Phase I trial: Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA Mutation Carriers
28
Phase II trial of the oral PARP inhibitor olaparib (AZD2281) in BRCA-deficient advanced ovarian cancer
29
PARP Inhibitors: Properties & Side Effects
30
Olaparib Clinical Trials
31
Ovarian cancer trials PARP 1 & 2 Inhibitors
32
Targeting Angiogenesis: VEGF
33
VEGF: Tyrosine kinase Inhibitor
34
Randomized phase II trial: Olaparib with Cediranib vs Olaparib alone in recurrent platinum sensitive
35
PARP Inhibitor Side effect Profile
36
In Summary
37
Targeting Therapies: Summary
Description:
Explore modern examples of ovarian cancer diagnoses and treatments in this informative webinar. Gain a comprehensive overview of ovarian cancer development, risk factors, and therapies, with a special focus on PARP inhibitors and their role in treatment. Dr. Annekathryn Goodman delves into topics such as cancer probability, symptom frequency, classification of ovarian cancer, regulatory pathways, standard of care, and hereditary susceptibility. Learn about targeted therapies, including PARP inhibitors and their mechanism of action, as well as clinical trials and side effect profiles. Discover the latest advancements in ovarian cancer treatment, including angiogenesis targeting and VEGF inhibitors. This 54-minute presentation offers valuable insights for healthcare professionals and those interested in understanding the complexities of ovarian cancer management.
PARP Inhibitors in Ovarian Cancer Treatment - Webinar - Ambry Genetics